JYNT — The Joint Corp.

Summary of The Joint Corp. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $14.8 million, a 13% increase year-over-year.
• Adjusted EBITDA: $2.2 million, up from $46,000 in Q1 2025, indicating improved operating leverage.
• Net Income: $1.1 million, compared to a net loss of $506,000 in Q1 2025.
• Cash Flow: Operating cash flow improved by $2.2 million, contributing to a $2.3 million increase in free cash flow.
• System-wide Sales: $126 million, a decline of 4.9% year-over-year.
• Comp Sales: Negative 4.2%, attributed to macroeconomic headwinds.

2. Strategic Updates and Business Highlights

• Refranchising Initiative: The company is nearing completion of its refranchising strategy, reducing company-owned clinics from 135 to just 3, enhancing its position as a pure-play franchisor.
• Joint 2.0 Initiative: Focused on operational efficiency and profitability, leading to improved financial results.
• Marketing and Member Growth: A national marketing campaign launched in November 2025 has shown sequential improvement in member growth. The company is also optimizing pricing and introducing flexible offerings to enhance patient retention.
• New Initiatives: Introduction of a B2B partnership program and a CareCredit program to improve patient access to care.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • System-wide sales expected between $519 million and $552 million.
  • Comp sales projected to range from negative 3% to positive 3%.
  • Consolidated adjusted EBITDA forecasted between $12.5 million and $13.5 million.
  • New franchise clinic openings expected to be between 30 and 35.
• Improvement Expectations: Comp sales are anticipated to improve throughout the year, with a shift to positive trends expected in Q3 and Q4.

4. Bad News, Challenges, or Points of Concern

• Comp Sales Decline: The negative 4.2% comp sales reflect ongoing macroeconomic challenges, including cost of living pressures.
• System-wide Sales Drop: The 4.9% decline in system-wide sales raises concerns about overall market performance.
• Clinic Count Reduction: The total clinic count decreased from 960 at year-end 2025 to 943, with closures outpacing new openings, indicating a need for careful management of the clinic portfolio.

5. Notable Q&A Insights

• Refranchising Timeline: Management expects to complete the refranchising transactions in the next couple of months, pending lease assignments.
• Drivers for Comp Sales Recovery: Improved patient retention strategies, national marketing efforts, and enhanced SEO practices are expected to drive comp sales recovery.
• Pricing Strategy: A $10 price increase is being implemented for new patients, with minimal pushback observed, suggesting effective value perception.
• G&A Expectations: G&A expenses are projected to decrease as the refranchising strategy concludes, with a goal to achieve a new run rate by the latter half of 2026.

Overall, The Joint Corp. is making significant strides in its transformation efforts, with promising financial results and strategic initiatives aimed at long-term growth, despite facing some short-term challenges in comp sales and market conditions.